Track 10: Challenges in Rare Diseases Treatment


There are around 7,000 rare diseases, which from a regulatory outlook are defined as those diseases where there are less than 200,000 patients in the US or that affect no more than five in 10,000 of the general population in the EU. Orphan drugs are medicinal products envisioned for diagnosis, prevention, and treatment of life-threatening rare diseases. They are "orphans" because the pharmaceutical industry has little interest under normal market conditions in developing and marketing drugs intended for only a small number of patients suffering from very rare conditions.



 


    Related Conference of Track 10: Challenges in Rare Diseases Treatment

    November 05-06, 2020

    9th Asia Pacific STD and Infectious Diseases Congress

    Tokyo, Japan
    February 15-16, 2021

    8th International Congress on Infectious Diseases

    London, UK
    May 10-11, 2021

    4th Global Experts Meeting on Infectious Diseases

    Singapore City, Singapore
    August 16-17, 2021

    13th Global Infections Conference

    Tokyo, Japan
    September 06-07, 2021

    11th World Congress on Rare Diseases and Orphan Drugs

    Berlin, Germany

    Track 10: Challenges in Rare Diseases Treatment Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in